Shuling Zhang, M.D., Ph.D.

Shuling Zhang, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 37, Room 3140
  • Bethesda, MD 20892
  • 301-594-6092


Dr. Shuling Zhang researches the plasmacytoma mouse model, a complex genetic process. His main goals include identifying tumor susceptibility/resistance genes and understanding how the individual allelic variants of these genes contribute, singly and in combination, to the susceptibility phenotype. Identification of the signaling pathways may contribute to the development of new strategies for preventing or treating human B cell tumors. Dr. Zhang is currently investigating the role of mTOR in B and T cell function, and the regulation of mTOR expression.

Areas of Expertise

Knock-out/in Mouse Models
Transcriptional Regulation
Immune Response


Selected Publications

B cell-specific deficiencies in mTOR limit humoral immune responses

Zhang S, Pruitt M, Tran D, Du Bois W, Zhang K, Patel R, Hoover S, Simpson RM, Simmons J, Gary J, Snapper CM, Casellas R, Mock BA.
J. Immunol.. 191: 1692-703, 2013. [ Journal Article ]

Increased mammalian lifespan and a segmental and tissue-specific slowing of aging after genetic reduction of mTOR expression

Wu JJ, Liu J, Chen EB, Wang JJ, Cao L, Narayan N, Fergusson MM, Rovira II, Allen M, Springer DA, Lago CU, Zhang S, DuBois W, Ward T, deCabo R, Gavrilova O, Mock B, Finkel T.
Cell Rep. 4: 913-20, 2013. [ Journal Article ]

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production

Zhang S, Readinger JA, DuBois W, Janka-Junttila M, Robinson R, Pruitt M, Bliskovsky V, Wu JZ, Sakakibara K, Patel J, Parent CA, Tessarollo L, Schwartzberg PL, Mock BA.
Blood. 117: 1228-38, 2011. [ Journal Article ]

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms

Simmons JK, Patel J, Michalowski A, Zhang S, Wei BR, Sullivan P, Gamache B, Felsenstein K, Kuehl WM, Simpson RM, Zingone A, Landgren O, Mock BA.
Mol Oncol. 8: 261-72, 2014. [ Journal Article ]

A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses

Smrž D, Bandara G, Zhang S, Mock BA, Beaven MA, Metcalfe DD, Gilfillan AM.
J. Immunol. Methods. 390: 52-62, 2013. [ Journal Article ]